Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions

References

• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153–e639. doi:10.1161/CIR.0000000000001052
   PubMed Web of Science ®Google Scholar
• Ghassibe-Sabbagh M, Platt DE, Youhanna S, et al. Genetic and environmental influences on total plasma homocysteine and its role in coronary artery disease risk. Atherosclerosis. 2012;222(1):180–186. doi:10.1016/j.atherosclerosis.2012.02.035
   PubMed Web of Science ®Google Scholar
• Keshet R, Boursi B, Maoz R, et al. Diagnostic and prognostic significance of serum C-reactive protein levels in patients admitted to the department of medicine. Am J Med Sci. 2009;337(4):248–255. doi:10.1097/MAJ.0b013e31818af6de
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi:10.1016/S0140-6736(04)17018-9
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Eng J Med. 2005;353(1):46–57. doi:10.1056/NEJMoa043175
   PubMed Web of Science ®Google Scholar
• Utermann G. Lipoprotein(a), in the Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Education; 2019. doi:https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225091040
   Google Scholar
• Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48–e60. doi:10.1161/ATV.0000000000000147
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–1282. doi:10.1016/j.cjca.2016.07.510
   PubMed Web of Science ®Google Scholar
• Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512. doi:10.1056/NEJMoa1109034
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated Lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470–477. doi:10.1016/j.jacc.2013.09.038
   PubMed Web of Science ®Google Scholar
• O’Riordan M. Lp(a) with CRP Levels Predict Death, MI Risk in Korean Cohort with Documented CAD. Medscape; 2015. doi:https://www.medscape.com/viewarticle/842190
   Google Scholar
• Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 1986;62(3):249–257. doi:10.1016/0021-9150(86)90099-7
   PubMed Web of Science ®Google Scholar
• Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74(4):758–765. doi:10.1161/01.CIR.74.4.758
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Koschinsky ML, Albers JJ, et al. Report of the national heart, lung, and blood institute workshop on Lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin Chem. 2003;49(11):1785–1796. doi:10.1373/clinchem.2003.023689
   PubMed Web of Science ®Google Scholar
• Utermann G, Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett. 1983;154(2):357–361. doi:10.1016/0014-5793(83)80182-3
   PubMed Web of Science ®Google Scholar
• Armstrong VW, Walli AK, Seidel D. Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). J Lipid Res. 1985;26(11):1314–1323. doi:10.1016/S0022-2275(20)34257-7
   PubMed Web of Science ®Google Scholar
• Gaubatz JW, Heideman C, Gotto AM, et al. Human plasma lipoprotein [a]. Structural properties. J Biol Chem. 1983;258(7):4582–4589. doi:10.1016/S0021-9258(18)32663-2
   PubMed Web of Science ®Google Scholar
• Enas EA, Varkey B, Dharmarajan TS, et al. Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J. 2019;71(2):99–112. doi:10.1016/j.ihj.2019.03.004
   PubMedGoogle Scholar
• Guan W, Cao J, Steffen BT, et al. Race is a key variable in assigning Lipoprotein(a) cutoff values for coronary heart disease risk assessment: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35:996–1001. doi:10.1161/ATVBAHA.114.304785
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi:10.1093/eurheartj/ehw272
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. doi:10.1093/eurheartj/ehq386
   PubMed Web of Science ®Google Scholar
• Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239–2245. doi:10.1161/ATVBAHA.116.308011
   PubMed Web of Science ®Google Scholar
• Enkhmaa B, Anuurad E, Berglund L. Lipoprotein(a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016;57(7):1111–1125. doi:10.1194/jlr.R051904
   PubMed Web of Science ®Google Scholar
• Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. South Dartmouth (MA): NCBI; 2000. doi:http://www.ncbi.nlm.nih.gov/books/NBK305896/
   Google Scholar
• Di Angelantonio E. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. doi:10.1001/jama.2009.1619
   PubMed Web of Science ®Google Scholar
• Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–1839. doi:10.1016/S0140-6736(07)61778-4
   PubMed Web of Science ®Google Scholar
• Xu J. Effect of Lipoprotein(a) on stroke recurrence attenuates at low LDL-C (low-density lipoprotein) and inflammation levels. Stroke. 2022;2022:1. doi:10.1161/STROKEAHA.121.034924
   Google Scholar
• Zhu L, Zheng J, Gao B, et al. The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels. BMC Cardiovasc Disord. 2022;22(1):171. doi:10.1186/s12872-022-02618-5
   PubMed Web of Science ®Google Scholar
• Ren Y, Pan W, Li X, et al. The predictive value of Lp(a) for adverse cardiovascular event in ACS patients with an achieved LDL-C target at follow up after PCI. J Cardiovasc Transl Res. 2022;15(1):67–74. doi:10.1007/s12265-021-10148-2
   PubMed Web of Science ®Google Scholar
• Li C, Chen Q, Zhang M, et al. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL. BMC Cardiovasc Disord. 2021;21(1):41. doi:10.1186/s12872-021-01861-6
   PubMed Web of Science ®Google Scholar
• Venkatesh PK, Caskey D, Reddy PC. Therapies to increase high-density lipoprotein cholesterol and their effect on cardiovascular outcomes and regression of atherosclerosis. Am J Med Sci. 2008;336(1):64–68. doi:10.1097/MAJ.0b013e31815d4419
   PubMed Web of Science ®Google Scholar
• Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol. 2006;98(11):1542–1549. doi:10.1016/j.amjcard.2006.06.059
   PubMed Web of Science ®Google Scholar
• Ragbir S, Farmer JA. Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep. 2010;12(5):343–348. doi:10.1007/s11883-010-0091-x
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Brewer HB, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48–60. doi:10.1038/nrcardio.2015.124
   PubMed Web of Science ®Google Scholar
• Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374–392. doi:10.1016/j.jacl.2019.04.010
   PubMed Web of Science ®Google Scholar
• Shapiro MD, Minnier J, Tavori H, et al. Relationship between low-density lipoprotein cholesterol and Lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc. 2019;8(4):e010932. doi:10.1161/JAHA.118.010932
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–1492. doi:10.1161/CIRCULATIONAHA.118.037184
   PubMed Web of Science ®Google Scholar
• Gencer B, Mach F. Potential of Lipoprotein(a)-lowering strategies in treating coronary artery disease. Drugs. 2020;80(3):229–239. doi:10.1007/s40265-019-01243-5
   PubMed Web of Science ®Google Scholar
• Lee PH, Ahn J-M, Chang M, et al. Left main coronary artery disease: secular trends in patient characteristics, treatments, and outcomes. J Am Coll Cardiol. 2016;68(11):1233–1246. doi:10.1016/j.jacc.2016.05.089
   PubMedGoogle Scholar
• Platt DE, Ghassibe-Sabbagh M, Youhanna S, et al. Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography. J Thromb Thrombolysis. 2015;39(1):15–22. doi:10.1007/s11239-014-1069-2
   PubMed Web of Science ®Google Scholar
• Makaryus AN, Dhama B, Raince J, et al. Coronary artery diameter as a risk factor for acute coronary syndromes in Asian-Indians. Am J Cardiol. 2005;96(6):778–780. doi:10.1016/j.amjcard.2005.05.018
   PubMed Web of Science ®Google Scholar
• Dodge JT Jr, Brown BG, Bolson EL, et al. Lumen diameter of normal human coronary arteries. Influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation. Circulation. 1992;86(1):232–246. doi:10.1161/01.CIR.86.1.232
   PubMed Web of Science ®Google Scholar
• Zhou FF, Liu Y-H, Ge P-C, et al. Coronary artery diameter is inversely associated with the severity of coronary lesions in patients undergoing coronary angiography. Cell Physiol Biochem. 2017;43(3):1247–1257. doi:10.1159/000481765
   PubMedGoogle Scholar
• MacAlpin RN, Abbasi AS, Grollman JH, et al. Human coronary artery size during life. Radiology. 1973;108(3):567–576. doi:10.1148/108.3.567
   PubMed Web of Science ®Google Scholar
• Deb A, Caplice NM. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol. 2004;27(5):258–264. doi:10.1002/clc.4960270503
   PubMed Web of Science ®Google Scholar
• Nielsen LB, Grønholdt MLM, Schroeder TV, et al. In vivo transfer of Lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol. 1997;17(5):905–911. doi:10.1161/01.ATV.17.5.905
   PubMed Web of Science ®Google Scholar
• Kostner K, Kostner G. Lipoprotein(a): a historical appraisal. J Lipid Res. 2016;2016:1.
   Google Scholar
• Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370(6489):460–462. doi:10.1038/370460a0
   PubMed Web of Science ®Google Scholar
• Grainger D, Kirschenlohr HL, Metcalfe JC, et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260(5114):1655–1658. doi:10.1126/science.8503012
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–2528. doi:10.1056/NEJMoa0902604
   PubMed Web of Science ®Google Scholar
• Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707–713. doi:10.1038/nature09270
   PubMed Web of Science ®Google Scholar
• Kassner U, Schlabs T, Rosada A, et al. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl. 2015;18:263–267. doi:10.1016/j.atherosclerosissup.2015.02.039
   PubMed Web of Science ®Google Scholar
• Yeang C, Karwatowska-Prokopczuk E, Su F, et al. Effect of pelacarsen on Lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79(11):1035–1046. doi:10.1016/j.jacc.2021.12.032
   PubMed Web of Science ®Google Scholar
• Novartis P. A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of Lipoprotein(a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease; 2022. Available from: clinicaltrials.gov. Accessed January 05, 2022.
   Google Scholar